Parkinson Disease

Research from A. Gordin and colleagues provide new insights into Parkinson disease

Published in Pain and Central Nervous System Week, December 24th, 2007

"In this review the effect of adjunct 5-nitrocatechol based COMT inhibitors, especially entacapone, on the pharmacokinetics and efficacy of levodopa is detailed. The safety and adverse events are considered based mainly on phase III trial data and extension studies," scientists in Espoo, Finland report.

"Entacapone used as an adjunct to regular or controlled-release levodopa preparations increased ON-time and reduced OFF-time by I to 2 h daily in Parkinson's disease patients with wearing-off. The daily levodopa dose could also be reduced. Entacapone was generally well tolerated. Dopaminergic adverse events, such as dyskinesia and nausea, could usually be handled by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week

Source: Pain and Central Nervous System Week (2007-12-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry